π Share this article The Global Health Body Raises Alert Over Critical Scarcity of Obesity Jabs Fewer than a tenth of people who could benefit from obesity jabs like Wegovy can access them, warns the WHO as it publishes its first recommendations on the drugs. Considering over a billion people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments. Per forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidelines affirms that excess weight is a long-term condition that can be treated with holistic and ongoing care," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key barriers to widespread availability to the jabs that can assist patients in reducing considerable weight, explains the body. Skinny Jab Scarcity Even in the current most favorable outlook, the production of GLP-1 therapies could only cover around 100 million people β fewer than 10% of eligible patients, according to the health organization. The advice urges nations and manufacturers to increase access, through approaches like patent sharing. A patent on semaglutide β the core component of a leading brand β is set to lapse in several nations in 2026. How Obesity Injections Work GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and increase satiety so individuals consume fewer calories. Patients commonly see weight reduction after several weeks of starting on the once-weekly jabs. Evidence indicates people may put most of the weight back on within a year of stopping the treatment, because their typical hunger return. To be above a healthy weight raises your chance for developing medical conditions, including diabetes, heart disease, stroke, and specific malignancies. Excess weight impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
Fewer than a tenth of people who could benefit from obesity jabs like Wegovy can access them, warns the WHO as it publishes its first recommendations on the drugs. Considering over a billion people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments. Per forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidelines affirms that excess weight is a long-term condition that can be treated with holistic and ongoing care," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key barriers to widespread availability to the jabs that can assist patients in reducing considerable weight, explains the body. Skinny Jab Scarcity Even in the current most favorable outlook, the production of GLP-1 therapies could only cover around 100 million people β fewer than 10% of eligible patients, according to the health organization. The advice urges nations and manufacturers to increase access, through approaches like patent sharing. A patent on semaglutide β the core component of a leading brand β is set to lapse in several nations in 2026. How Obesity Injections Work GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and increase satiety so individuals consume fewer calories. Patients commonly see weight reduction after several weeks of starting on the once-weekly jabs. Evidence indicates people may put most of the weight back on within a year of stopping the treatment, because their typical hunger return. To be above a healthy weight raises your chance for developing medical conditions, including diabetes, heart disease, stroke, and specific malignancies. Excess weight impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.